321 related articles for article (PubMed ID: 28284752)
41. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Dabbeni-Sala F; Di Santo S ; Franceschini D; Skaper SD; Giusti P
FASEB J; 2001 Jan; 15(1):164-170. PubMed ID: 11149904
[TBL] [Abstract][Full Text] [Related]
42. The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat.
Zare K; Eidi A; Roghani M; Rohani AH
Metab Brain Dis; 2015 Feb; 30(1):205-13. PubMed ID: 25123753
[TBL] [Abstract][Full Text] [Related]
43. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.
Liu CQ; Chen Z; Liu FX; Hu DN; Luo JH
Neuropharmacology; 2007 Dec; 53(7):832-41. PubMed ID: 17919665
[TBL] [Abstract][Full Text] [Related]
44. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
[TBL] [Abstract][Full Text] [Related]
45. Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease
Zhou H; Shao M; Yang X; Li C; Cui G; Gao C; Di L; Zhong H; Wang Y; Zhang Z; Lee SM
Oxid Med Cell Longev; 2019; 2019():8169125. PubMed ID: 31827703
[TBL] [Abstract][Full Text] [Related]
46. Protective Effect of Tocotrienol on In Vitro and In Vivo Models of Parkinson's Disease.
Matsura T
J Nutr Sci Vitaminol (Tokyo); 2019; 65(Supplement):S51-S53. PubMed ID: 31619646
[TBL] [Abstract][Full Text] [Related]
47. Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Ghalami J; Baluchnejad Mojarad T; Mansouri M; Khamse S; Roghani M
Basic Clin Neurosci; 2021; 12(1):43-56. PubMed ID: 33995926
[TBL] [Abstract][Full Text] [Related]
48. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
Ganser C; Papazoglou A; Just L; Nikkhah G
Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
[TBL] [Abstract][Full Text] [Related]
49. Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra.
Li LY; Zhao XL; Fei XF; Gu ZL; Qin ZH; Liang ZQ
Acta Pharmacol Sin; 2008 May; 29(5):539-47. PubMed ID: 18430361
[TBL] [Abstract][Full Text] [Related]
50. Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA.
Chan HH; Kumar S; Zhuo L
Eur J Pharmacol; 2013 Sep; 715(1-3):405-13. PubMed ID: 23652161
[TBL] [Abstract][Full Text] [Related]
51. Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease.
Khan MM; Raza SS; Javed H; Ahmad A; Khan A; Islam F; Safhi MM; Islam F
Neurotox Res; 2012 Jul; 22(1):1-15. PubMed ID: 22194158
[TBL] [Abstract][Full Text] [Related]
52. Neuroprotective Effects of Sulphated Agaran from Marine Alga Gracilaria cornea in Rat 6-Hydroxydopamine Parkinson's Disease Model: Behavioural, Neurochemical and Transcriptional Alterations.
Souza RB; Frota AF; Sousa RS; Cezario NA; Santos TB; Souza LM; Coura CO; Monteiro VS; Cristino Filho G; Vasconcelos SM; da Cunha RM; Aguiar LM; Benevides NM
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):159-170. PubMed ID: 27612165
[TBL] [Abstract][Full Text] [Related]
53. Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease.
Leikas JV; Kohtala S; Theilmann W; Jalkanen AJ; Forsberg MM; Rantamäki T
J Neurochem; 2017 Aug; 142(3):456-463. PubMed ID: 28488766
[TBL] [Abstract][Full Text] [Related]
54. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
55. The estrogen receptor β-PI3K/Akt pathway mediates the cytoprotective effects of tocotrienol in a cellular Parkinson's disease model.
Nakaso K; Tajima N; Horikoshi Y; Nakasone M; Hanaki T; Kamizaki K; Matsura T
Biochim Biophys Acta; 2014 Sep; 1842(9):1303-12. PubMed ID: 24768803
[TBL] [Abstract][Full Text] [Related]
56. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
[TBL] [Abstract][Full Text] [Related]
57. Carvacrol Protects Against 6-Hydroxydopamine-Induced Neurotoxicity in In Vivo and In Vitro Models of Parkinson's Disease.
Manouchehrabadi M; Farhadi M; Azizi Z; Torkaman-Boutorabi A
Neurotox Res; 2020 Jan; 37(1):156-170. PubMed ID: 31364033
[TBL] [Abstract][Full Text] [Related]
58. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
59. Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures.
Kääriäinen TM; Piltonen M; Ossola B; Kekki H; Lehtonen S; Nenonen T; Lecklin A; Raasmaja A; Männistö PT
Brain Res; 2008 Apr; 1203():149-59. PubMed ID: 18329008
[TBL] [Abstract][Full Text] [Related]
60. Guanosine protects glial cells against 6-hydroxydopamine toxicity.
Giuliani P; Ballerini P; Buccella S; Ciccarelli R; Rathbone MP; Romano S; D'Alimonte I; Caciagli F; Di Iorio P; Pokorski M
Adv Exp Med Biol; 2015; 837():23-33. PubMed ID: 25310956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
